We were concerned by Razeghinejad et al's recent publication on intraocular pressure (IOP) immediately following trans-scleral cyclophotocoagulation (TSCPC) or cyclodiode laser treatment [1] . They found a worryingly high rate of significant IOP rise (IOP spike), with 90% of their patients receiving intravenous mannitol. Therefore, we audited our own practice.
This prospective audit was approved by our local Clinical Audit Department. Our default protocol is 40 shots at 1500 mW, 1500 ms, using the G-probe [2] . Power is reduced if there are repeated 'pops'. Additional IOPlowering medications are not normally given. For the audit, we measured IOP before the anaesthetic, after anaesthetic, and immediately after TSCPC, with the patient in the same position. We used the Tonopen AVIA (Reichert, NY, USA) and averaged three 'reliable' IOP's for each time-point. Any IOP rise that we considered 'potentially clinically significant' was managed according to clinical judgement.
We audited 35 consecutive procedures in 5 months. The only exclusions were eyes which could not have IOP measured by Tonopen (one un-cooperative patient, a few with very-high initial IOP). All had local anaesthesia (LA), either peribulbar or sub-Tenon's. 'Pops' occurred in six eyes (17%). There was a low rate of IOP spikes (Fig. 1) . There was only one 'potentially clinically significant' IOP rise, and this resolved without active intervention. The IOP was 27 mmHg before LA, 23 mmHg after LA, and 35 mmHg after TSCPC (40 shots at 1500 mW, 1500 ms; three 'pops'). The patient was simply observed; 20 minutes later the IOP was Fig. 1 The intra-ocular pressure (IOP) profile after cyclodiode laser treatment. We used our standard protocol of 40 shots at 1500 mW, 1500 ms. Two patients had an IOP rise that was considered 'potentially clinically significant' (red lines), though both resolved without medication. See text for further detail 32 mmHg. No additional IOP-lowering medication was given, IOP was 4 mmHg one week later. Another patient had an IOP rise following peribulbar LA; this resolved with massage.
With our technique, we were reassured by the absence of sight-threatening IOP spikes. We attribute this to the low power settings: 40 shots at 1500 mW, 1500 ms, with reduced power if pops are heard. By contrast, Razeghinejad's team used higher initial power (2000 mW, 2000 ms), and seemed to increase the power until they heard 'pops' (maximum 3000 mW, 4000 ms). Razeghinejad speculated that the 'pops' probably cause IOP spikes, due to intraocular gas bubbles. Our audit indicates that the lower-power protocol and minimising 'pops' is preferable for TSCPC.
